FY2026 Q2 Earnings Announcement
From Transformation to Growth Acceleration
Horizon One: Transforming for Growth

from the beginning

FY2026 Q2 Earnings Announcement

Important Notice

AGENDA

Business Highlights

H1 Results on Track; Steady Progress Against FY2026 Priorities

ORZEYFUL Now Approved in the U.S., Japan & China

MIMRYLO Now Available in the U.S

3 Transformative Medicines Setting Takeda

A New Era Defined by Two Growth Horizons

Financial Highlights

FY2026 H1 Results: Transformation Savings Largely Offset

Transformation Program Initiatives on Track

Revenue Growth of Core In-line Brands & New Launches

Transformation Program Helping to Fund Growth Investments

Reported Operating Profit Reflects end of VYVANSE

Upgrading FY2026 Full-year Outlook Mainly due to FX

FY2026 Core Operating Profit Forecast Increased Mainly due to FX

Pipeline Highlights

VERDICT Treat-to-Target Trial Shows Treating to Disease Clearance

3 Transformative Medicines Setting Takeda on a

A Greater Proportion of Zasocitinib-Treated Patients Achieved

Delivering Our Late-Stage Programs that are Starting to

Delivering Our Late-Stage Programs that are Starting to

In Advanced Gastric Cancer Patients

Closing Remarks

Steady Progress Against Horizon One Priorities

Q&A SESSION

• Q&A SESSION1

• Q&A SESSION2

• Q&A SESSION3

• Q&A SESSION4

• Q&A SESSION5

• Q&A SESSION6

• Q&A SESSION7

Appendix